Cogent Biosciences Statistics
Total Valuation
COGT has a market cap or net worth of $1.00 billion. The enterprise value is $785.87 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
COGT has 110.46 million shares outstanding. The number of shares has increased by 29.32% in one year.
| Current Share Class | 110.46M |
| Shares Outstanding | 110.46M |
| Shares Change (YoY) | +29.32% |
| Shares Change (QoQ) | +11.01% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 73.38% |
| Float | 64.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.92 |
| P/TBV Ratio | 4.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.44, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.44 |
| Quick Ratio | 6.32 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -78.47% and return on invested capital (ROIC) is -49.73%.
| Return on Equity (ROE) | -78.47% |
| Return on Assets (ROA) | -44.02% |
| Return on Capital (ROIC) | -49.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.48M |
| Employee Count | 164 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.78% in the last 52 weeks. The beta is 0.02, so COGT's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | +13.78% |
| 50-Day Moving Average | 10.89 |
| 200-Day Moving Average | 8.79 |
| Relative Strength Index (RSI) | 31.87 |
| Average Volume (20 Days) | 1,497,610 |
Short Selling Information
The latest short interest is 8.43 million, so 7.63% of the outstanding shares have been sold short.
| Short Interest | 8.43M |
| Short Previous Month | 8.58M |
| Short % of Shares Out | 7.63% |
| Short % of Float | 13.13% |
| Short Ratio (days to cover) | 8.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -260.43M |
| Pretax Income | -227.05M |
| Net Income | -242.30M |
| EBITDA | -258.01M |
| EBIT | -260.43M |
| Earnings Per Share (EPS) | -$2.48 |
Full Income StatementBalance Sheet
The company has $335.52 million in cash and $17.83 million in debt, giving a net cash position of $327.72 million or $2.97 per share.
| Cash & Cash Equivalents | 335.52M |
| Total Debt | 17.83M |
| Net Cash | 327.72M |
| Net Cash Per Share | $2.97 |
| Equity (Book Value) | 314.66M |
| Book Value Per Share | 1.85 |
| Working Capital | 288.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$191.28 million and capital expenditures -$813,000, giving a free cash flow of -$192.10 million.
| Operating Cash Flow | -191.28M |
| Capital Expenditures | -813,000 |
| Free Cash Flow | -192.10M |
| FCF Per Share | -$1.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |